#verseaophthalmics – Verséa
 
HomeTag

#verseaophthalmics

WEST POINT OPTICAL GROUP, LLC AND VERSÉA OPHTHALMICS, INC. ANNOUNCE PARTNERSHIP SUPPLY AGREEMENT FOR  BIOVANCE®AND BIOVANCE® 3L OCULAR

MASON, OH and TAMPA, FL., April 3, 2024 — West Point Optical Group, LLC (“WPOG”), providing quality patient care by developing experienced, well-rounded vision health teams within its 86 Pearle Vision stores, and Verséa Ophthalmics, Inc. (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced...

Verséa Ophthalmics and Celularity Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications

TAMPA, FL. and FLORHAM PARK, N.J., July 27, 2023 — Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, and Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that the companies have entered into...

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

7/25/2022, Tampa, FL – Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow  Readers. The company focuses on delivering innovative Tear-based Point-of-Care (T-POC) testing and biologic solutions that...

Verséa™ Ophthalmics at the Hawaii Eye 2023

Verséa Ophthalmics invites you to attend the Hawaiian Eye 2023 – Disruptive Innovations Symposium on January 16th from 1pm – 2:30pm HST where Dr. Rob Sambursky, our President, will be presenting the latest Eye Care innovations: Novel, Tear-based Point-of-care (POC) diagnostic platform with 2 quantitative tests, Complementary regenerative therapeutics. These innovative solutions will help you...

Verséa™ Ophthalmics – proud sponsor of 2022 CEDARS/ASPENS Annual Meeting

Verséa Ophthalmics is a proud sponsor of this year’s 2022 CEDARS/ASPENS Annual Meeting, taking place today and tomorrow at JW Marriott Camelback, Scottsdale (AZ). CEDARS/ASPENS is a not-for-profit society whose mission is to expand the knowledge of ophthalmic surgery and foster excellence in patient care through clinical experience, peer-to-peer exchange, and practice education. Their mission...

Verséa™ Ophthalmics featured at the Eyes On 2023 Corporate Exhibit Hall Interview series

As part of the corporate exhibit hall interview series at the Eyes On 2023, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Brittany J. McMurren, OD. During the interview, titled “A Deep Dive into New Testing & Therapeutic Innovations”  Rob Sambursky, MD presented new testing and therapeutic innovations that Verséa Ophthalmics is bringing to...